Psychedelics as Novel Therapeutics for Chronic Pain in Veterinary Medicine: A Hypothesis-Driven Protocol Using Low-Dose 1-Cyclopropionyl-D-lysergic Acid Diethylamide (1cp-LSD) in Canine Osteoarthritis
Elisa Hernández-Álvarez, Andrea Acosta-Dacal, Octavio P. Luzardo, Luis Alberto Henríquez-Hernández · 2025
Read Psychedelics as Novel Therapeutics for Chronic Pain in Veterinary Medicine: A Hypothesis-Driven Protocol Using Low-Dose 1-Cyclopropionyl-D-lysergic Acid Diethylamide (1cp-LSD) in Canine Osteoarthritis by Elisa Hernández-Álvarez, Andrea Acosta-Dacal, Octavio P. Luzardo, Luis Alberto Henríquez-Hernández (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12785101.txt.
Description
Elisa Hernandez-Alvarez and co-authors lay out, in a 2025 protocol, a trial of low dose psychedelic treatment for chronic pain in dogs with osteoarthritis. Low dose psychedelics have shown promise for chronic pain in people. Their use in veterinary medicine is unexplored, and arthritic dogs are a natural first case, since pain control options for them are limited.
About 24 privately owned dogs with diagnosed arthritis will take part. The design is randomized and placebo controlled, with caregivers blinded to which group their dog is in. Dogs receive tiny, below perception doses of a legal LSD analogue by mouth, on an intermittent schedule over 30 days. Their usual pain medicines continue throughout, to protect welfare. Outcomes include a standard canine brief pain inventory. A careful first trial could open a new class of pain care for aging pets.
Catalog record
| CREATOR | Elisa Hernández-Álvarez, Andrea Acosta-Dacal, Octavio P. Luzardo, Luis Alberto Henríquez-Hernández |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |